Clarity bolsters antibody pre-targeting with IP from leading global cancer center
Sydney, Australia 7 August 2023 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce an exclusive license from Memorial Sloan Kettering Cancer Center (MSK). The license is to intellectual property that…